NBP earnings

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholdersAppointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the CompanyAdvancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval PathwayProgressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durabilityMaintained a strong balance sheet with $215.9 million in cash, cash equivalents, short-term investments, and equity investment

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMDVIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mmPotentially best-in-class durability with a favorable safety profile and no dose-limiting toxicityPhase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027Conference Call and Webcast today, March 09 at 9:00 AM ET ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or t